||reduced response to anti-osteoporosis drugs
rs2297480 is a SNP in the FDPS gene, which encodes an enzyme in the mevalonate pathway and therefore might alter the response to amino-bisphonate (drug) treatment of postmenopausal osteoporosis.
A study of 234 Danish postmenopausal women treated for at least 2 years with amino-bisphonates concluded that rs2297480(C;C) homozygotes do not respond as successfully as (A;A) or (A;C) genotypes.[PMID 18687167]
[PMID 17368768] Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women.
[PMID 19150398] Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse.
[PMID 20191015] Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women.
[PMID 21151198] Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates.
[PMID 21196316] Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.